Nucs AI operates in the healthcare and oncology sectors, developing artificial intelligence tools for prostate cancer diagnostics. The company's platform is designed to automate the detection, staging, and treatment response evaluation of the disease, applying expertise in medical imaging and computer vision. It is headquartered in San Francisco and Berlin.
The company offers a suite of solutions, including DeepPSMA, SelectPSMA, and TrackPSMA. Reported metrics indicate its system can achieve 92% accuracy in identifying PSMA-positive lesions, process scans in under a minute, and reduce manual work in over 50% of cases.
Nucs AI secured $3.5 million in seed funding. Its stated mission is to provide clinicians with faster and more precise diagnostic tools.
